News | December 03, 2007

Abiomed’s Heart Pump Supports High-Risk Patient in Trial

December 4, 2007 – The Impella 2.5, a catheter-based heart pump device, supports high-risk patient’s weakened heart in the Abiomed PROTECT I trial conducted at the Texas Heart Institute at St. Luke’s Episcopal Hospital.

Texas Heart Institute at St. Luke’s Episcopal Hospital was one of the few facilities chosen to participate in the Abiomed PROTECT I trial for the Impella 2.5, the first FDA-approved trial for prophylactic, or preventative, use of a device during high-risk percutaneous coronary intervention (PCI) procedures.

In February 2007, one of 20 patients enrolled in the Impella 2.5 PROTECT I trial who had undergone an unsuccessful coronary artery bypass surgery eight months prior to enrollment in the trial, was not a candidate for additional surgical revascualarization and was considered too high risk for standard percutaneous coronary intervention (PCI) procedures. The patient was enrolled in the Protect I Trial, which was designed to evaluate the Impella 2.5 system as a support device to allow PCI procedures in very high-risk patients.

The Impella 2.5 device was advanced into the patient’s heart via his femoral artery in the hospital’s cardiac catheterization lab. While the Impella system supported his weakened heart, multiple stents were safely inserted into the coronary arteries, relieving the obstructions. The patient reportedly returned to a normal life shortly after the Impella 2.5 supported procedure and remains free of chest pain nine months after the procedure.

Abiomed’s Impella 2.5 is a left ventricular assist device (VAD), which is inserted percutaneously in the cardiac catheterization lab, providing patients with up to 2.5 liters of blood flow per minute. It is the world's smallest VAD and has been used to treat conditions such as acute myocardial infarction (heart attack), cardiogenic shock and low output syndrome under CE Mark approval in Europe.

“The Impella system allowed us to safely treat a patient population previously considered too high risk for standard PCI procedures,” said Andrew Civitello, M.D., principal investigator of the PROTECT I trial at Texas Heart Institute at St. Luke’s Episcopal Hospital.

Pranav Loyalka, M.D., a co-investigator in the trial, added, “In the future, we hope to treat other patient populations, including those in cardiogenic shock or those that have recently suffered from an acute myocardial infarction, and revolutionize the way coronary artery disease is treated.”

For more information: www.abiomed.com and www.texasheart.org

Related Content

Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters | October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters | August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters | March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Merit Medical Systems, SwiftNINJA Steerable Microcatheter, FDA 510(k) clearance
Technology | Catheters | November 09, 2016
November 9, 2016 — Merit Medical Systems Inc.
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters | July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
Roxwood Medical, MicroCross Catheter, full U.S. launch

Image courtesy of Roxwood Medical

Technology | Catheters | January 07, 2016
Roxwood Medical Inc. reported that more than 500 patients have been successfully treated as part of the initial limited...
Overlay Init